Needham analyst Gil Blum maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $150.00. The company's shares closed last Thursday at $71.82. According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -22.5% and a 27.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $127.83 average price target, an 86.3% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-sarepta-therapeutics-srpt?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.